PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsHaloperidol
Haloperidol
Haldol, Haloperidol (haloperidol) is a small molecule pharmaceutical. Haloperidol was first approved as Haldol on 1982-01-01. It is used to treat child behavior disorders, psychotic disorders, schizophrenia, schizophrenia spectrum and other psychotic disorders, and substance withdrawal syndrome amongst others in the USA. The pharmaceutical is active against D(3) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 2A, and D(2) dopamine receptor. In addition, it is known to target D(1A) dopamine receptor, G protein-activated inward rectifier potassium channel 2, D(1B) dopamine receptor, 5-hydroxytryptamine receptor 7, voltage-gated delayed rectifier potassium channel KCNH1; potassium voltage-gated channel subfamily H member 1, 5-hydroxytryptamine receptor 1D, 5-hydroxytryptamine receptor 2B, histamine H1 receptor, and 5-hydroxytryptamine receptor 1A.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
hereditary congenital and neonatal diseases and abnormalitiesD009358
signs and symptoms pathological conditionsD013568
chemically-induced disordersD064419
mental disordersD001523
Trade Name
FDA
EMA
Haloperidol (discontinued: Haldol, Haloperidol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Haloperidol
Tradename
Company
Number
Date
Products
HALDOLJohnson & JohnsonN-015921 DISCN1982-01-01
6 products, RLD
HALDOL SOLUTABJohnson & JohnsonN-017079 DISCN1982-01-01
1 products
Hide discontinued
Haloperidol lactate
Tradename
Company
Number
Date
Products
HALDOLJohnson & JohnsonN-015923 DISCN1982-01-01
1 products, RLD
HALDOLJohnson & JohnsonN-015922 DISCN1982-01-01
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
haldol decanoateNew Drug Application2025-01-30
haloperidolANDA2025-04-09
haloperidol decanoateANDA2025-02-28
haloperidol lactateANDA2024-12-30
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05A: Antipsychotics
— N05AD: Butyrophenone derivatives, antipsychotics
— N05AD01: Haloperidol
HCPCS
Code
Description
J1630
Injection, haloperidol, up to 5 mg
J1631
Injection, haloperidol decanoate, per 50 mg
Clinical
Clinical Trials
195 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Psychomotor agitationD011595——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHaloperidol
INNhaloperidol
Description
Haloperidol is a compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. It has a role as a serotonergic antagonist, a first generation antipsychotic, a dopaminergic antagonist, an antidyskinesia agent and an antiemetic. It is a hydroxypiperidine, an organofluorine compound, an aromatic ketone, a tertiary alcohol and a member of monochlorobenzenes.
Classification
Small molecule
Drug classantipsychotics (haloperidol type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
Identifiers
PDB—
CAS-ID52-86-8
RxCUI—
ChEMBL IDCHEMBL54
ChEBI ID5613
PubChem CID3559
DrugBankDB00502
UNII IDJ6292F8L3D (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KCNH1
KCNH1
Organism
Homo sapiens
Gene name
KCNH1
Gene synonyms
EAG, EAG1
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily H member 1
Protein synonyms
EAG channel 1, ether-a-go-go 1, Ether-a-go-go potassium channel 1, ether-a-go-go, Drosophila, homolog of, h-eag, hEAG1, potassium channel, voltage gated eag related subfamily H, member 1, potassium voltage-gated channel, subfamily H (eag-related), member 1, Voltage-gated potassium channel subunit Kv10.1
Uniprot ID
Mouse ortholog
Kcnh1 (16510)
potassium voltage-gated channel subfamily H member 1 (Q60603)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Haloperidol
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 41,362 documents
View more details
Safety
Black-box Warning
Black-box warning for: Haldol decanoate, Haloperidol, Haloperidol decanoate, Haloperidol lactate
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
27,002 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use